Your browser doesn't support javascript.
loading
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.
Cattaneo, C; Di Blasi, R; Skert, C; Candoni, A; Martino, B; Di Renzo, N; Delia, M; Ballanti, S; Marchesi, F; Mancini, V; Orciuolo, E; Cesaro, S; Prezioso, L; Fanci, R; Nadali, G; Chierichini, A; Facchini, L; Picardi, M; Malagola, M; Orlando, V; Trecarichi, E M; Tumbarello, M; Aversa, F; Rossi, G; Pagano, L.
Afiliación
  • Cattaneo C; Haematology, Spedali Civili, 25123, Brescia, Italy. chiara.cattaneo@libero.it.
  • Di Blasi R; Institute of Haematology, Università Cattolica S. Cuore, Rome, Italy.
  • Skert C; Chair of Haematology, Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy.
  • Candoni A; Division of Haematology and Stem Cell Transplantation, University Hospital of Udine, Udine, Italy.
  • Martino B; Haematology Unit, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy.
  • Di Renzo N; UOC di Ematologia e Trapianto di Cellule Staminali", PO "Vito Fazzi", Lecce, Italy.
  • Delia M; Haematology Division, University of Bari, Bari, Italy.
  • Ballanti S; Institute of Haematology and Stem Cell transplantation, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia, Italy.
  • Marchesi F; Haematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Rome, Italy.
  • Mancini V; Department of Haematology and Oncology, A.O. Ospedale Niguarda Cà Granda, Milan, Italy.
  • Orciuolo E; Haematology Unit, Azienda Ospedaliero-Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy.
  • Cesaro S; Pediatric Haematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Prezioso L; Haematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Fanci R; Haematology Unit, Careggi Hospital and University of Florence, Florence, Italy.
  • Nadali G; Section of Hematology, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy.
  • Chierichini A; UOC Ematologia Azienda Ospedaliera S. Giovanni Addolorata, Rome, Italy.
  • Facchini L; Haematology Unit, AO S. Maria Nuova, IRCCS, Reggio Emilia, Italy.
  • Picardi M; Dipartimento di Scienze Biomediche Avanzate, Università Federico II Napoli, Naples, Italy.
  • Malagola M; Chair of Haematology, Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy.
  • Orlando V; Haematology, Spedali Civili, 25123, Brescia, Italy.
  • Trecarichi EM; Institute of Infectious Disease, Università Cattolica S. Cuore, Rome, Italy.
  • Tumbarello M; Institute of Infectious Disease, Università Cattolica S. Cuore, Rome, Italy.
  • Aversa F; Haematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Rossi G; Haematology, Spedali Civili, 25123, Brescia, Italy.
  • Pagano L; Institute of Haematology, Università Cattolica S. Cuore, Rome, Italy.
Ann Hematol ; 97(9): 1717-1726, 2018 Sep.
Article en En | MEDLINE | ID: mdl-29705860
ABSTRACT
Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All patients showing MDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE. In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%). The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of colonization.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Bacteriemia / Neoplasias Hematológicas / Farmacorresistencia Bacteriana Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Bacteriemia / Neoplasias Hematológicas / Farmacorresistencia Bacteriana Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Italia